Indivior Pharmaceuticals (INDV) Revenue & Revenue Breakdown
Indivior Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$1.24B
Latest Revenue (Q)
$314.00M
Main Segment (Y)
Reportable Segment
Main Geography (Y)
UNITED STATES
Indivior Pharmaceuticals Revenue by Period
Indivior Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | $1.24B | 4.29% |
| 2024-12-31 | $1.19B | 8.69% |
| 2023-12-31 | $1.09B | 21.31% |
| 2022-12-31 | $901.00M | 13.91% |
| 2021-12-31 | $791.00M | 22.26% |
| 2020-12-31 | $647.00M | -17.58% |
| 2019-12-31 | $785.00M | -18.22% |
| 2018-12-31 | $959.92M | -16.39% |
| 2017-12-31 | $1.15B | 18.50% |
| 2016-12-31 | $968.89M | - |
Indivior Pharmaceuticals generated $1.24B in revenue during NA 2025, up 4.29% compared to the previous quarter, and up 191.50% compared to the same period a year ago.
Indivior Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-09-30 | $314.00M | 3.97% |
| 2025-06-30 | $302.00M | 13.53% |
| 2025-03-31 | $266.00M | -11.04% |
| 2024-12-31 | $299.00M | -2.61% |
| 2024-09-30 | $307.00M | 2.47% |
| 2024-06-30 | $299.61M | 5.97% |
| 2024-03-31 | $282.74M | -5.96% |
| 2023-12-31 | $300.65M | 15.10% |
| 2023-09-30 | $261.20M | -6.66% |
| 2023-06-30 | $279.85M | 8.97% |
| 2023-03-31 | $256.80M | 2.92% |
| 2022-12-31 | $249.52M | 13.30% |
| 2022-09-30 | $220.24M | 2.70% |
| 2022-06-30 | $214.44M | 5.78% |
| 2022-03-31 | $202.72M | -8.96% |
| 2021-12-31 | $222.67M | - |
Indivior Pharmaceuticals generated $314.00M in revenue during Q3 2025, up 3.97% compared to the previous quarter, and up 104.80% compared to the same period a year ago.
Indivior Pharmaceuticals Revenue Breakdown
Indivior Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 25 |
|---|---|
| Reportable Segment | $1.24B |
Indivior Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 25: Reportable Segment (100.00%).
Quarterly Revenue by Product
| Product/Service | Dec 25 | Sep 25 | Jun 25 | Mar 25 |
|---|---|---|---|---|
| Reportable Segment | $357.00M | $314.00M | $302.00M | $266.00M |
Indivior Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: Reportable Segment (100.00%).
Indivior Pharmaceuticals Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 24 |
|---|---|
| UNITED STATES | $3.00M |
Indivior Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 24: UNITED STATES (100.00%).
Indivior Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| OPCH | Option Care Health | $5.65B | $1.44B |
| AMRX | Amneal Pharmaceuticals | $3.02B | $784.51M |
| LNTH | Lantheus | $1.54B | $384.01M |
| INDV | Indivior Pharmaceuticals | $1.24B | $314.00M |
| ACAD | ACADIA Pharmaceuticals | $957.80M | $278.63M |
| SUPN | Supernus Pharmaceuticals | $718.95M | $192.10B |
| HNGE | Hinge Health | $587.86M | $154.21M |
| ADMA | ADMA Biologics | $510.17M | $134.22M |
| CRNX | Crinetics Pharmaceuticals | $5.42M | $143.00K |
| VKTX | Viking Therapeutics | - | - |
| PRAX | Praxis Precision Medicines | - | - |